rs750085275

Variant summary

Our verdict is Likely benign. The variant received -5 ACMG points: 0P and 5B. BP4_StrongBP6

The NM_002691.4(POLD1):​c.2388+5G>A variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000439 in 1,593,864 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 2/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.000079 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000040 ( 0 hom. )

Consequence

POLD1
NM_002691.4 splice_region, intron

Scores

2
Splicing: ADA: 0.8888
2

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:5B:2

Conservation

PhyloP100: 0.692

Publications

1 publications found
Variant links:
Genes affected
POLD1 (HGNC:9175): (DNA polymerase delta 1, catalytic subunit) This gene encodes the 125-kDa catalytic subunit of DNA polymerase delta. DNA polymerase delta possesses both polymerase and 3' to 5' exonuclease activity and plays a critical role in DNA replication and repair. Alternatively spliced transcript variants have been observed for this gene, and a pseudogene of this gene is located on the long arm of chromosome 6. [provided by RefSeq, Mar 2012]
POLD1 Gene-Disease associations (from GenCC):
  • POLD1-related polyposis and colorectal cancer syndrome
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • colorectal cancer, susceptibility to, 10
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Genomics England PanelApp
  • mandibular hypoplasia-deafness-progeroid syndrome
    Inheritance: AD, AR Classification: STRONG, SUPPORTIVE, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), PanelApp Australia, Genomics England PanelApp, Ambry Genetics, Orphanet, G2P
  • Polymerase proofreading-related adenomatous polyposis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • immunodeficiency 120
    Inheritance: AR Classification: LIMITED Submitted by: Ambry Genetics
  • non-severe combined immunodeficiency due to polymerase delta deficiency
    Inheritance: AR Classification: LIMITED Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -5 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.8).
BP6
Variant 19-50413884-G-A is Benign according to our data. Variant chr19-50413884-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 408012.We mark this variant Likely_benign, oryginal submission is: [Conflicting_classifications_of_pathogenicity].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
POLD1NM_002691.4 linkc.2388+5G>A splice_region_variant, intron_variant Intron 19 of 26 ENST00000440232.7 NP_002682.2 P28340A0A024R4F4Q59FA0

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
POLD1ENST00000440232.7 linkc.2388+5G>A splice_region_variant, intron_variant Intron 19 of 26 1 NM_002691.4 ENSP00000406046.1 P28340

Frequencies

GnomAD3 genomes
AF:
0.0000788
AC:
12
AN:
152240
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000724
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000131
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000735
Gnomad OTH
AF:
0.000955
GnomAD2 exomes
AF:
0.0000565
AC:
13
AN:
229954
AF XY:
0.0000323
show subpopulations
Gnomad AFR exome
AF:
0.000125
Gnomad AMR exome
AF:
0.000126
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000562
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000577
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000402
AC:
58
AN:
1441624
Hom.:
0
Cov.:
31
AF XY:
0.0000405
AC XY:
29
AN XY:
715364
show subpopulations
African (AFR)
AF:
0.0000302
AC:
1
AN:
33062
American (AMR)
AF:
0.0000940
AC:
4
AN:
42550
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
24628
East Asian (EAS)
AF:
0.0000253
AC:
1
AN:
39558
South Asian (SAS)
AF:
0.00
AC:
0
AN:
82922
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
52278
Middle Eastern (MID)
AF:
0.000710
AC:
4
AN:
5632
European-Non Finnish (NFE)
AF:
0.0000381
AC:
42
AN:
1101426
Other (OTH)
AF:
0.000101
AC:
6
AN:
59568
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.473
Heterozygous variant carriers
0
4
8
12
16
20
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000788
AC:
12
AN:
152240
Hom.:
0
Cov.:
33
AF XY:
0.0000807
AC XY:
6
AN XY:
74384
show subpopulations
African (AFR)
AF:
0.0000724
AC:
3
AN:
41458
American (AMR)
AF:
0.000131
AC:
2
AN:
15290
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5202
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4838
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10626
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000735
AC:
5
AN:
68032
Other (OTH)
AF:
0.000955
AC:
2
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.521
Heterozygous variant carriers
0
1
2
3
4
5
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000109
Hom.:
0
Bravo
AF:
0.0000604

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:5Benign:2
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2
Mar 20, 2020
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 02, 2024
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

In silico analysis suggests this variant may impact gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; Observed in individuals with personal and/or family history of breast cancer (PMID: 34326862, 34646395, 35534704); This variant is associated with the following publications: (PMID: 34326862, 34646395, 35534704) -

Colorectal cancer, susceptibility to, 10 Uncertain:2
Jan 26, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change falls in intron 19 of the POLD1 gene. It does not directly change the encoded amino acid sequence of the POLD1 protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs750085275, gnomAD 0.01%). This variant has been observed in individual(s) with breast cancer (PMID: 34646395, 35534704). ClinVar contains an entry for this variant (Variation ID: 408012). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant is associated with inconclusive levels of altered splicing (internal data). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

May 28, 2019
Mendelics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hereditary cancer-predisposing syndrome Benign:2
Jun 01, 2020
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Feb 19, 2021
Sema4, Sema4
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:curation

- -

not specified Uncertain:1
Feb 17, 2025
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: POLD1 c.2388+5G>A alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Four predict the variant weakens the canonical intron 19, 5' splicing donor site. However, these predictions have yet to be confirmed by peer reviewed functional studies. In-house RNA analysis demonstrated inconclusive levels of in-frame skipping of exon 19 resulting in r.2251_2388del (p.Val752_Val797del), however, the in-vivo relevance of this finding is unclear (internal data). To our knowledge, no pathogenic/likely pathogenic variants have been reported in exon 19. The variant allele was found at a frequency of 5.7e-05 in 229954 control chromosomes. The observed variant frequency exceeds the estimated maximal expected allele frequency for a pathogenic variant in POLD1 causing Mandibular Hypoplasia, Deafness, Progeroid Features, And Lipodystrophy Syndrome phenotype (6.3e-07) or susceptibility to colorectal cancer (1.4e-05). c.2388+5G>A has been reported in the literature as a VUS in settings of multigene panel testing for hereditary cancer but has not been reported in individuals with Autosomal Dominant Mandibular Hypoplasia, Deafness, Progeroid Features, And Lipodystrophy Syndrome. The association of POLD1 with Autosomal Recessive Immunodeficiency 120 is limited at this moment and loss of function of POLD1 is not an established mechanism of disease. Therefore, these report(s) do not provide unequivocal conclusions about association of the variant with any of the POLD1-related disorders. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 34326862, 34646395, 35534704). ClinVar contains an entry for this variant (Variation ID: 408012). Based on the evidence outlined above, the variant was classified as VUS-possibly benign. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.80
CADD
Benign
22
DANN
Benign
0.49
PhyloP100
0.69
PromoterAI
-0.080
Neutral
Mutation Taster
=67/33
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
0.89
dbscSNV1_RF
Benign
0.59
SpliceAI score (max)
0.27
Details are displayed if max score is > 0.2
DS_DG_spliceai
0.27
Position offset: -43

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs750085275; hg19: chr19-50917141; API